A prospective study of ceftriaxone treatment in acute pyelonephritis caused by extended-spectrum beta-lactamase-producing bacteria

Journal of the Medical Association of Thailand

Volumn 91, Issue 8, 2008, Pages 1172-1181

  Suankratay, Chusana ^a   Jutivorakool, Kamonwan ^b   Jirajariyavej, Supunnee ^c  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b CHONBURI HOSPITAL   (Thailand)

^c Taksin Hospital   (Thailand)

Author keywords

Acute pyelonephritis; Ceftriaxone; Escherichia coli; Extended spectrum beta lactamases; Klebsiella pneumoniae

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; CARBAPENEM; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; COTRIMOXAZOLE; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; IMIPENEM; MEROPENEM; SULPERAZON;

ACUTE PYELONEPHRITIS; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; DRUG SUBSTITUTION; ESCHERICHIA COLI; FEMALE; HUMAN; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; NONHUMAN; PROSPECTIVE STUDY; PROTEUS MIRABILIS; TREATMENT FAILURE; TREATMENT RESPONSE;

ACUTE DISEASE; AGED; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CASE-CONTROL STUDIES; CEFTRIAXONE; DISEASE SUSCEPTIBILITY; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ESCHERICHIA COLI; FEMALE; HUMANS; KLEBSIELLA PNEUMONIAE; PROSPECTIVE STUDIES; PROTEUS MIRABILIS; PYELONEPHRITIS;

EID: 50949126364     PISSN: 01252208     EISSN: 01252208     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Knothe H, Shah P, Krcmery V, Antal M, Mitsuhashi S. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection 1983; 11: 315-7.
2. Livermore DM. Beta-lactamase-mediated resistance and opportunities for its control. J Antimicrob Chemother 1998; 41(Suppl D): 25-41.
3. Pitout JD, Sanders CC, Sanders WE Jr. Antimicrobial resistance with focus on beta-lactam resistance in gram-negative bacilli. Am J Med 1997; 103: 51-9.
4. Emery CL, Weymouth LA. Detection and clinical significance of extended-spectrum beta-lactamases in a tertiary-care medical center. J Clin Microbiol 1997; 35: 2061-7.
5. Quinn JP. Clinical significance of extended-spectrum beta-lactamases. Eur J Clin Microbiol Infect Dis 1994; 13(Suppl 1): S39-42.
6. Bradford PA. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001; 14: 933-51.
7. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 to June 2002, issued August 2002 Am J Infect Control 2002; 30: 458-75.
8. Paterson DL, Ko WC, Von Gottberg A, Mohapatra S, Casellas JM, Goossens H, et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis 2004; 39: 31-7.
9. Winokur PL, Canton R, Casellas JM, Legakis N. Variations in the prevalence of strains expressing an extended-spectrum beta-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region. Clin Infect Dis 2001; 32(Suppl 2): S94-103.
10. Bell JM, Turnidge JD, Gales AC, Pfaller MA, Jones RN. Prevalence of extended spectrum beta-lactamase (ESBL)-producing clinical isolates in the Asia-Pacific region and South Africa: regional results from SENTRY Antimicrobial Surveillance Program (1998-99). Diagn Microbiol Infect Dis 2002; 42: 193-8.
11. Paterson DL, Ko WC, Von Gottberg A, Casellas JM, Mulazimoglu L, Klugman KP, et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 2001; 39: 2206-12.
12. Brun-Buisson C, Legrand P, Philippon A, Montravers F, Ansquer M, Duval J. Transferable enzymatic resistance to third-generation cephalosporins during nosocomial outbreak of multi-resistant Klebsiella pneumoniae. Lancet 1987; 2: 302-6.
13. Meyer KS, Urban C, Eagan JA, Berger BJ, Rahal JJ. Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins. Ann Intern Med 1993; 119: 353-8.
14. Paterson DL. Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs). Clin Microbiol Infect 2000; 6: 460-3.
15. Schiappa DA, Hayden MK, Matushek MG, Hashemi FN, Sullivan J, Smith KY, et al. Ceftazidime-resistant Klebsiella pneumoniae and Escherichia coli bloodstream infection: a case-control and molecular epidemiologic investigation. J Infect Dis 1996; 174: 529-36.
16. Kim YK, Pai H, Lee HJ, Park SE, Choi EH, Kim J, et al. Bloodstream infections by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome. Antimicrob Agents Chemother 2002; 46: 1481-91.
17. Cunha BA. Pseudomonas aeruginosa: resistance and therapy. Semin Respir Infect 2002; 17: 231-9.
18. Bradford PA, Urban C, Mariano N, Projan SJ, Rahal JJ, Bush K. Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated AmpC beta-lactamase, and the foss of an outer membrane protein. Antimicrob Agents Chemother 1997; 41: 563-9.
19. Ahmad M, Urban C, Mariano N, Bradford PA, Calcagni E, Projan SJ, et al. Clinical characteristics and molecular epidemiology associated with imipenem-resistant Klebsiella pneumoniae. Clin Infect Dis 1999; 29: 352-5.
20. National Committee for Clinical Laboratory Standards. Performance Standard for Antimicrobial Susceptibility Testing: Fourteenth Information Supplement M100-S14. Wayne, PA: National Committee for Clinical Laboratory Standards; 2004: 32-5.
21. Safdar N, Maki DG. The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, enterococcus, gram-negative bacilli, Clostridium difficile, and Candida. Ann Intern Med 2002; 136: 834-44.
22. Mangeney N, Niel P, Paul G, Faubert E, Hue S, Dupeyron C, et al. A 5-year epidemiological study of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae isolates in a medium- and long-stay neurological unit. J Appl Microbiol 2000; 88: 504-11.
23. Lucet JC, Chevret S, Decre D, Vanjak D, Macrez A, Bedos JP, et al. Outbreak of multiply resistant enterobacteriaceae in an intensive care unit: epidemiology and risk factors for acquisition. Clin Infect Dis 1996; 22: 430-6.
24. De Champs C, Rouby D, Guelon D, Sirot J, Sirot D, Beytout D, et al. A case-control study of an outbreak of infections caused by Klebsiella pneumoniae strains producing CTX-1 (TEM-3) beta-lactamase. J Hosp Infect 1991; 18: 5-13.
25. Pena C, Pujol M, Ricart A, Ardanuy C, Ayats J, Linares J, et al. Risk factors for faecal carriage of Klebsiella pneumoniae producing extended spectrum beta-lactamase (ESBL-KP) in the intensive care unit. J Hosp Infect 1997; 35: 9-16.
26. Menashe G, Borer A, Yagupsky P, Peled N, Gilad J, Fraser D, et al. Clinical significance and impact on mortality of extended-spectrum beta lactamase-producing Enterobacteriaceae isolates in nosocomial bacteremia. Scand J Infect Dis 2001; 33: 188-93.
27. Piroth L, Aube H, Doise JM, Vincent-Martin M. Spread of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae: are beta-lactamase inhibitors of therapeutic value? Clin Infect Dis 1998; 27: 76-80.
28. D'Agata E, Venkataraman L, DeGirolami P, Weigel L, Samore M, Tenover F. The molecular and clinical epidemiology of enterobacteriaceae-producing extended-spectrum beta-lactamase in a tertiary care hospital. J Infect 1998; 36: 279-85.
29. Pena C, Pujol M, Ardanuy C, Ricart A, Pallares R, Linares J, et al. Epidemiology and successful control of a large outbreak due to Klebsiella pneumoniae producing extended-spectrum beta-lactamases. Antimicrob Agents Chemother 1998; 42: 53-8.
30. Paterson DL, Ko WC, Von Gottberg A, Mohapatra S, Casellas JM, Goossens H, et al. International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial Infections. Ann Intern Med 2004; 140: 26-32.
31. Du B, Long Y, Liu H, Chen D, Liu D, Xu Y, et al. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae bloodstream infection: risk factors and clinical outcome. Intensive Care Med 2002; 28: 1718-23.
32. Lin MF, Huang ML, Lai SH. Risk factors in the acquisition of extended-spectrum beta-lactamase Klebsiella pneumoniae: a case-control study in a district teaching hospital in Taiwan. J Hosp Infect 2003; 53: 39-45.
33. Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 2001; 32: 1162-71.
34. Martinez-Martinez L, Pascual A, Jacoby GA. Quinolone resistance from a transferable plasmid. Lancet 1998; 351: 797-9.
35. Ho PL, Chan WM, Tsang KW, Wong SS, Young K. Bacteremia caused by Escherichia coli producing extended-spectrum beta-lactamase: a case-control study of risk factors and outcomes. Scand J Infect Dis 2002; 34: 567-73.
36. Kim BN, Woo JH, Kim MN, Ryu J, Kim YS. Clinical implications of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae bacteraemia. J Hosp Infect 2002; 52: 99-106.
37. Kang CI, Kim SH, Kim DM, Park WB, Lee KD, Kim HB, et al. Risk factors for and clinical outcomes of bloodstream infections caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae. Infect Control Hosp Epidemiol 2004; 25: 860-7.
38. Ramphal R, Ambrose PG. Extended-spectrum beta-lactamases and clinical outcomes: current data. Clin Infect Dis 2006; 42(Suppl 4): S164-S172.
39. Wong-Beringer A. Therapeutic challenges associated with extended-spectrum, beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Pharmacotherapy 2001; 21: 583-92.
40. Zanetti G, Bally F, Greub G, Garbino J, Kinge T, Lew D, et al. Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study. Antimicrob Agents Chemother 2003; 47: 3442-7.
41. Burgess DS, Hall RG, Lewis JS, Jorgensen JH, Patterson JE. Clinical and microbiologic analysis of a hospital's extended-spectrum beta-lactamase- producing isolates over a 2-year period. Pharmacotherapy 2003; 23: 1232-7.